CHICAGO / Mar 23, 2023 / Business Wire / Veradigm® (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions, announced today that Black Book, a healthcare-centric market research and public opinion research and consulting company, has ranked Practice Fusion first for Allergy and Immunology and second for Rheumatology within its 2023 Ambulatory EHR by Physician Specialty category.
Practice Fusion, a Veradigm Network solution, is a cloud-based electronic health record (EHR) system designed specifically for independent practices, aiming to cater to the needs of medical professionals, service providers, and patients. It supports over 31,000 clinicians and helps drive better care for 5 million patients a month. Practice Fusion’s comprehensive system ensures secure and reliable access to all patient and practice information. The EHR is designed to streamline administrative tasks and provide clinicians with the tools they need to provide the best possible patient care. Practice Fusion's wide range of features, including clinical charting, lab and imaging integrations, and e-prescribing, helps practice staff save time and increase efficiency.
“Black Book’s survey highlights Veradigm’s commitment to providing independent practices with the support, cloud technology and cost-effective tools they need,” said Tom Langan, President and Chief Commercial Officer of Veradigm. “We are very proud of this honor from Black Book and are committed to empowering independent healthcare providers.”
About Veradigm®
Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully. For more information on Veradigm, visit http://www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, and YouTube
© 2023 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.
Last Trade: | US$4.24 |
Daily Change: | -2.57 -37.74 |
Daily Volume: | 600 |
Market Cap: | US$456.390M |
February 27, 2024 February 22, 2024 January 10, 2024 January 09, 2024 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load